Hantz Financial Services Inc. Sells 263 Shares of Boston Scientific Co. (NYSE:BSX)

Hantz Financial Services Inc. lessened its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.8% in the 4th quarter, HoldingsChannel reports. The fund owned 33,104 shares of the medical equipment provider’s stock after selling 263 shares during the period. Hantz Financial Services Inc.’s holdings in Boston Scientific were worth $2,957,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BSX. Sunbelt Securities Inc. lifted its holdings in shares of Boston Scientific by 85.8% during the 2nd quarter. Sunbelt Securities Inc. now owns 1,213 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 560 shares during the last quarter. Quarry LP purchased a new stake in Boston Scientific in the second quarter valued at about $33,000. EP Wealth Advisors LLC boosted its holdings in Boston Scientific by 4.1% in the second quarter. EP Wealth Advisors LLC now owns 13,066 shares of the medical equipment provider’s stock worth $1,006,000 after acquiring an additional 514 shares in the last quarter. Truist Financial Corp grew its stake in shares of Boston Scientific by 1.1% during the second quarter. Truist Financial Corp now owns 214,594 shares of the medical equipment provider’s stock worth $16,526,000 after acquiring an additional 2,254 shares during the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Boston Scientific by 2.9% during the second quarter. Cetera Investment Advisers now owns 295,984 shares of the medical equipment provider’s stock valued at $22,794,000 after acquiring an additional 8,399 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BSX. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday. Bank of America boosted their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. TD Cowen raised their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. BTIG Research boosted their price target on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Citigroup raised their price objective on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Trading Up 0.2 %

Shares of BSX stock opened at $102.97 on Friday. The stock has a 50 day simple moving average of $92.99 and a 200-day simple moving average of $85.93. Boston Scientific Co. has a 1-year low of $62.63 and a 1-year high of $104.25. The company has a market cap of $151.75 billion, a price-to-earnings ratio of 85.10, a PEG ratio of 2.63 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company’s stock, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock valued at $2,702,261 over the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.